Washington Drug Letter

April 16, 2012 | Vol. 44 No. 16

FDA Restricts BioMed IRB After Two Failed Inspections

The FDA has halted approval of new trials and enrollment in ongoing studies reviewed by the investigational review board (IRB) BioMed after two negative assessments of the board’s work.

This article is viewable by subscribers only. To view this article, please select an option below.

Subscribe
Print This Page
RSS
Free Trial
Archives
Sample PDF

FDA: IRBs Must Review IND Decisions, Investigator Qualifications, Sites Indiana Hospital IRB Warned for Inadequate Pediatric Protections Clinical Site’s Problems Won’t Trip Up Launch of First HIV Home Test Good Communication Can Minimize Study Disruptions During IRB Transfers: Draft Guidance

Home
Advertising/Sponsorships
About Us
Contact Us
Site Map
Privacy Policy

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA.
Phone (703) 538-7600 - Fax (703) 538-7676 - Toll free (888) 838-5578.